Successful treatment of resistant antiglomerular basement membrane antibody positivity with mycophenolic acid.
Anti-glomerular basement membrane (GBM) antibody disease may progress to end-stage renal failure, requiring either dialysis or renal transplantation. In patients with end-stage renal disease (ESRD) due to anti-GBM-ab disease, the recurrence rate after transplantation is as high as 50% (2) and delaying renal transplantation until circulating anti-GBM antibody levels have been undetectable for at least 12 months reduces the recurrence rate to 5-15%. We report a case of ESRD due to renal limited anti-GBM disease with circulating anti-GBM-ab resistant to standard treatment approach who achieved undetectable anti-GBM-ab with mycophenolic acid.
Kiykim
Ahmet Alper
AA
Department of Internal Medicine, Division of Nephrology, Mersin Universitiy, School of Medicine, Mersin, Turkey. aakiykim@yahoo.com
Horoz
Mehmet
M
Gok
Ebru
E
D000328:Adult; D001323:Autoantibodies / Q000097:blood*; D001327:Autoimmune Diseases / Q000150:complications / Q000188:drug therapy* / Q000276:immunology; D001706:Biopsy; D005260:Female; D005921:Glomerulonephritis / Q000150:complications / Q000188:drug therapy* / Q000276:immunology; D006801:Humans; D007668:Kidney / Q000473:pathology; D007676:Kidney Failure, Chronic / Q000209:etiology; D009173:Mycophenolic Acid / Q000627:therapeutic use*; D016896:Treatment Outcome
D001323:Autoantibodies; C051951:antiglomerular basement membrane antibody; D009173:Mycophenolic Acid